Top

Cancer Cell International

Published in:

Open Access 01-12-2019 | Breast Cancer | Primary research

High long non-coding RNA NORAD expression predicts poor prognosis and promotes breast cancer progression by regulating TGF-β pathway

Authors: Ke Zhou, Qin Ou, Geng Wang, Wenqi Zhang, Yin Hao, Wenfang Li

Published in: Cancer Cell International | Issue 1/2019

Abstract

Background

To investigate the expression and significance of long noncoding RNA NORAD (lncRNA-NORAD) in breast cancer.

Methods

Q-PCR was adopted to detect the mRNA expression of lncRNA-NORAD in breast cancer and adjacent tissues, survival analysis to compare the low-expression groups with the Kaplan–Meier method. Knockout of lncRNA-NORAD was adopted to observe the effects on the cell proliferation, migration and invasion of breast cancer in vitro and in vivo. The TGF-β/RUNX2 signaling pathway was observed by Western blot after the knockout of lncRNA-NORAD.

Results

Increased expression of lncRNA-NORAD in breast cancer tissues promotes proliferation, invasion and migration of breast cancer cells and correlated with worse prognosis. LncRNA-NORAD activated TGF-β/RUNX2 signaling pathway in breast cancer cells.

Conclusions

These results strongly suggested that lncRNA-NORAD might play an important role in breast cancer progression and potentially be a new therapeutic target.

Brewer HR, Jones ME, Schoemaker MJ, Ashworth A, Anthony J. Family history and risk of breast cancer: an analysis accounting for family structure. Breast Cancer Res Treat. 2017;165(1):193–200. https://doi.org/10.1007/s10549-017-4325-2.CrossRefPubMedPubMedCentral

Sun Y-S, Zhao Z, Yang Z-N, Fang X, Hang-Jing L, et al. Risk factors and preventions of breast cancer. Int J Biol Sci. 2017;13(11):1387–97.CrossRef

Xue W, Tudoran OM, Calin GA, Ivan M. The many faces of long noncoding RNAs in cancer. Antioxid Redox Signal. 2018;29(9):922–35. https://doi.org/10.1089/ars.2017.7293.CrossRef

Schmitz SU, Grote P, Herrmann BG. Mechanisms of long noncoding RNA function in development and disease. Cell Mol Life Sci. 2016;73:2491–509. https://doi.org/10.1007/s00018-016-2174-5.CrossRefPubMedPubMedCentral

Sun M, Kraus WL. From discovery to function: the expanding roles of long noncoding RNAs in physiology and disease. Endocr Rev. 2015;36(1):25–64.CrossRef

Arun G, Diermeier S, Akerman M, Kung-Chi Chang J, Wilkinson E, et al. Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss. Genes Dev. 2016;30(1):34–51. https://doi.org/10.1101/gad.270959.115.CrossRefPubMedPubMedCentral

Han F, Wang C, Wang Y, Zhang L. Long noncoding RNA ATB promotes osteosarcoma cell proliferation, migration and invasion by suppressing miR-200s. Am J Cancer Res. 2017;7(4):770–83.PubMedPubMedCentral

Wang L, Du L, Duan W, Yan S, Xie Y, Wang C. Overexpression of long noncoding RNA NORAD in colorectal cancer associates with tumor progression. Onco Targets Ther. 2018;11:6757–66. https://doi.org/10.2147/ott.s176354.CrossRefPubMedPubMedCentral

Kawasaki N, Miwa T, Hokari S, Sakurai T, Ohmori K, Miyauchi K, Miyazono K, Koinuma D. Long noncoding RNA NORAD regulates transforming growth factor-β signaling and epithelial-to-mesenchymal transition-like phenotype. Cancer Sci. 2018;109(7):2211–20. https://doi.org/10.1111/cas.13626 (Epub 2018 May 29).CrossRefPubMedPubMedCentral

10.

Wu X, Lim ZF, Li Z, Gu L, Ma W, Zhou Q, Su H, Wang X, Yang X, Zhang Z. NORAD expression is associated with adverse prognosis in esophageal squamous cell carcinoma. Oncol Res Treat. 2017;40(6):370–4. https://doi.org/10.1159/000464465.CrossRefPubMed

11.

Akhurst RJ, Hata A. Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov. 2012;11(10):790–811. https://doi.org/10.1038/nrd3810.CrossRefPubMedPubMedCentral

12.

Huang JJ, Blobe GC. Dichotomous roles of TGF-β in human cancer. Biochem Soc Trans. 2016;44(5):1441–54. https://doi.org/10.1042/BST20160065.CrossRefPubMedPubMedCentral

13.

Connolly EC, Freimuth J, Akhurst RJ. Complexities of TGF-β targeted cancer therapy. Int J Biol Sci. 2012;8(7):964–78. https://doi.org/10.7150/ijbs.4564.CrossRefPubMedPubMedCentral

14.

Yanyuan W, Tran T, Dwabe S, Sarkissyan M, Kim J, et al. A83-01 inhibits TGF-β-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells. Breast Cancer Res Treat. 2017;163(3):449–60. https://doi.org/10.1007/s10549-017-4211-y.CrossRef

15.

Yu Y, Xiao C-H, Tan L-D, Wang Q-S, Li X-Q, Feng Y-M. Cancer-associated fibroblasts induce epithelial–mesenchymal transition of breast cancer cells through paracrine TGF-β signalling. Br J Cancer. 2014;110(3):724–32. https://doi.org/10.1038/bjc.2013.768.CrossRefPubMed

16.

Ge C, Zhao G, Li Y, Li H, Zhao X, et al. Role of Runx2 phosphorylation in prostate cancer and association with metastatic disease. Oncogene. 2016;35(3):366–76. https://doi.org/10.1038/onc.2015.91.CrossRefPubMed

17.

Zheng-Jun G, Lang Y, Feng Q, Yan-Xia W, Xi Y, et al. Transcription factor RUNX2 up-regulates chemokine receptor CXCR1 to promote invasive and metastatic potentials of human gastric cancer. Oncotarget. 2016;7(15):20999–1012. https://doi.org/10.18632/oncotarget.8236.CrossRef

18.

Jessica LB, Moran C, Saranya C, Keli R, Alexander D, et al. RUNX2 and TAZ-dependent signaling pathways regulate soluble E-cadherin levels and tumorsphere formation in breast cancer cells. Oncotarget. 2015;6(29):28132–50. https://doi.org/10.18632/oncotarget.4654.CrossRef

19.

Tandon M, Chen Z, Pratap J. Runx2 activates PI3 K/Akt signaling via mTORC2 regulation in invasive breast cancer cells. Breast Cancer Res. 2014;16(1):R16. https://doi.org/10.1186/bcr3611.CrossRefPubMedPubMedCentral

20.

Sancisi V, Manzotti G, Gugnoni M, Rossi T, Gandolfi G, et al. RUNX2 expression in thyroid and breast cancer requires the cooperation of three non-redundant enhancers under the control of BRD4 and c-JUN. Nucleic Acids Res. 2017;45(19):11249–67. https://doi.org/10.1093/nar/gkx802.CrossRefPubMedPubMedCentral

21.

Chimge N-O, Baniwal SK, Little GH, Chen Y-b, Kahn M, et al. Regulation of breast cancer metastasis by Runx2 and estrogen signaling: the role of SNAI2. Breast Cancer Res. 2011;13(6):R127.CrossRef

Title: High long non-coding RNA NORAD expression predicts poor prognosis and promotes breast cancer progression by regulating TGF-β pathway
Authors: Ke Zhou
Qin Ou
Geng Wang
Wenqi Zhang
Yin Hao
Wenfang Li
Publication date: 01-12-2019
Publisher: BioMed Central
Keywords: Breast Cancer
Breast Cancer
Published in: Cancer Cell International / Issue 1/2019
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-019-0781-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2019

Smoking history influences the prognostic value of peripheral naïve CD4+ T cells in advanced non-small cell lung cancer

Prognostic significance of cyclin D3 expression in malignancy patients: a meta-analysis

TRIM27 promotes the development of esophagus cancer via regulating PTEN/AKT signaling pathway

Prognostic impact of platelet-to-lymphocyte ratio on diffuse large B-cell lymphoma: a meta-analysis

Low BCL9 expression inhibited ovarian epithelial malignant tumor progression by decreasing proliferation, migration, and increasing apoptosis to cancer cells

H/ACA box small nucleolar RNA 7B acts as an oncogene and a potential prognostic biomarker in breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer